Ghassan K. Abou-Alfa, MD, discusses a retrospective analysis that evaluated embolization Vs embolization plus systemic therapy in patients with hepatocellular carcinoma & metastatic disease.
Related Videos In Liver Cancer
Ahmed Kaseb, ESMO 2019 – Nivolumab plus ipilimumab in HCC
We joined Ahmed Kaseb (M.D. Anderson Cancer Center) at ESMO 2019 to discuss recent findings from the randomised, open-label, perioperative phase 2 study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma (NCT03222076). Questions 1. What are the major unmet needs in the treatment of resectable hepatocellular carcinoma (HCC)? (00:02) 2. […]
Viktor Grünwald- ECCO 2017
Combination therapy with lenvatinib and everolimus in metastatic renal cell carcinoma – why did this combination succeed where others failed? Katrina Mountfort, Touch Medical Media, Reading, UK, Metastatic renal cell carcinoma (mRCC) is associated with a poor prognosis, with a 5-year survival rate of only 8%.1 Within the last 10 years, a number of potent […]
Jeff Evans, ASCO 2018 – Development of combination lenvatinib plus pembrolizumab for the treatment of hepatocellular carcinoma
Jeff Evans, of the University of Glasgow, UK, talks to us about the advances in the clinical development of lenvatinib and its potential use in combination with pembrolizumab for the treatment of hepatocellular carcinoma. 1. What is the latest progress on the clinical development of lenvatinib for the treatment of unresectable hepatocellular carcinoma both in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!